Develops investigational treatments for bladder cancer and neurological disorders, aimed at patients with those conditions.
10-K for FY2025, filed Mar 19, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 19, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$13.9MView ↗
Pipeline refocus
Earlier, Relmada focused on esmethadone for depression and other central nervous system disorders. The latest report describes a bladder cancer drug candidate and a neurosteroid for neurological disorders, and says development of esmethadone ended.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 19, 2026Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a clinical-stage biotechnology company focused on…View ↗
Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a publicly traded, clinical-stage biotechnology…View ↗
Following the 2024 REL-1017 setback and subsequent post hoc analyses, the program was terminated effective July 7, 2025.View ↗
Currently, our lead product, NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is…View ↗
Our second product, sepranolone is a novel neurosteroid epimer of allopregnanolone. Sepranolone is being developed for the potential…View ↗
Loading...